Key result
Recent guidelines and trials highlight novel pharmacological therapies targeting specific mechanisms to improve HFrEF prognosis.
Why the study?
New mechanisms involved in heart failure progression and specific therapies have been identified as management strategies continue to evolve to improve quality of life in HFrEF.
This review summarizes recent guidelines and emerging pharmacological therapies for the management of HFrEF.
Heart failure management has been repeatedly reviewed over time. This strategy has resulted in improved quality of life, especially in patients with heart failure with reduced ejection fraction (HFrEF). It is for this reason that new mechanisms involved in the development and progression of heart failure, along with specific therapies, have been identified. This review focuses on the most recent guidelines of therapeutic interventions, trials that explore novel therapies, and also new molecules that could improve prognosis of different HFrEF phenotypes.
No takes yet. Share an insight, caveat, or question.
Moloce et al. (2022) conducted a review in Chronic Heart Failure with Reduced Ejection Fraction (HFrEF). Pharmacological therapies was evaluated. Recent guidelines and trials highlight novel pharmacological therapies and new molecules that target specific mechanisms to improve the prognosis of different HFrEF phenotypes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: